Myocardial glucose uptake evaluated by positron emission tomography and fluorodeoxyglucose during hyperglycemic clamp in IDDM patients. Role of free fatty acid and insulin levels

Monti, L. D.; Lucignani, G.; Landoni, C.; Moresco, R. M.; Piatti, P.; Stefani, I.; Pozza, G.; Fazio, F.

doi:10.2337/diabetes.44.5.537

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the acute ischemic stage, cardiac FAO was basically normal (67), and FA metabolism gradually decreased with HF progression from the early stage to the decompensated stage (52, 59, 67, 68). While there was a notable rise in cardiac FA uptake and oxidation, during the early stage of DM (65,(69)(70)(71)(72)(73)(74). However, with the progression of DM, high rates of cardiac FA β-oxidation negatively affect cardiac efficiency (myocardial oxygen consumption/cardiac work) in humans (74, 75) and animals (76)(77)(78).…”

Section: Effects Of Sglt2i On Cardiac Fa Metabolismmentioning

confidence: 99%

The changes of cardiac energy metabolism with sodium-glucose transporter 2 inhibitor therapy

Su,

Ji,

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Background/aimsTo investigate the specific effects of s odium-glucose transporter 2 inhibitor (SGLT2i) on cardiac energy metabolism.MethodsA systematic literature search was conducted in eight databases. The retrieved studies were screened according to the inclusion and exclusion criteria, and relevant information was extracted according to the purpose of the study. Two researchers independently screened the studies, extracted information, and assessed article quality.ResultsThe results of the 34 included studies (including 10 clinical and 24 animal studies) showed that SGLT2i inhibited cardiac glucose uptake and glycolysis, but promoted fatty acid (FA) metabolism in most disease states. SGLT2i upregulated ketone metabolism, improved the structure and functions of myocardial mitochondria, alleviated oxidative stress of cardiomyocytes in all literatures. SGLT2i increased cardiac glucose oxidation in diabetes mellitus (DM) and cardiac FA metabolism in heart failure (HF). However, the regulatory effects of SGLT2i on cardiac FA metabolism in DM and cardiac glucose oxidation in HF varied with disease types, stages, and intervention duration of SGLT2i.ConclusionSGLT2i improved the efficiency of cardiac energy production by regulating FA, glucose and ketone metabolism, improving mitochondria structure and functions, and decreasing oxidative stress of cardiomyocytes under pathological conditions. Thus, SGLT2i is deemed to exert a benign regulatory effect on cardiac metabolic disorders in various diseases.Systematic review registrationhttps://www.crd.york.ac.uk/, PROSPERO (CRD42023484295).

show abstract

Section: Effects Of Sglt2i On Cardiac Fa Metabolismmentioning

confidence: 99%

The changes of cardiac energy metabolism with sodium-glucose transporter 2 inhibitor therapy

Su,

Ji,

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…It is, however, difficult to extrapolate the data obtained in animal studies (ex vivo) to humans, because there may be differences related to the experimental preparation or the species. For example, insulin increases myocardial glucose and 2-DG uptake in the isolated rat heart preparation (18) much less than it does in humans in vivo (3,13,26). Also, recent studies examining myocardial kinetics of [ 18 F]FDG in human subjects showed [ 18 F]FDG to quantitatively trace glucose uptake both basally (LC ϭ 1.44) and during insulin infusion (LC ϭ 0.99) (29).…”

Section: Discussionmentioning

confidence: 99%

Direct measurement of the lumped constant for 2-deoxy-[1-¹⁴C]glucose in vivo in human skeletal muscle

Utriainen

Lovisatti

Mäkimattila

et al. 2000

American Journal of Physiology-Endocrinology and Metabolism

View full text Add to dashboard Cite

The lumped constant (LC) is used to convert the clearance rate of 2-deoxy-D-glucose (2-DG(CR)) to that of glucose (Glc(CR)). There are currently no data to validate the widely used assumption of an LC of 1.0 for human skeletal muscle. We determined the LC for 2-deoxy-[1-(14)C]glucose (2-DG) in 18 normal male subjects (age, 29+/- 2 yr; body mass index, 24.8+/-0.8 kg/m(2)) after an overnight fast and during physiological (1 mU x kg(-1) x min(-1) insulin infusion for 180 min) and supraphysiological (5 mU x kg(-1) x min(-1) insulin infusion for 180 min) hyperinsulinemic conditions. Normoglycemia was maintained with the euglycemic clamp technique. The LC was measured directly with the use of a novel triple tracer-based method. [3-(3)H]glucose, 2-[1-(14)C]DG, and [(12)C]mannitol (Man) were injected as a bolus into the brachial artery. The concentrations of [3-(3)H]glucose and 2-[1-(14)C]DG (dpm/ml plasma) and of Man (micromol/l) were determined in 50 blood samples withdrawn from the ipsilateral deep forearm vein over 15 min after the bolus injection. The LC was calculated by a formula involving blood flow calculated from Man and the Glc(CR) and 2-DG(CR). The LC averaged 1.26+/-0.08 (range 1.06-1.43), 1.15+/-0.05 (0.99-1.39), and 1.18+/-0.05 (0.97-1.37) under fasting conditions and during the 1 and 5 mU x kg(-1). min(-1) insulin infusions (not significant between the different insulin concentrations, mean LC = 1.2, P<0.01 vs. 1.0). We conclude that, in normal subjects, the LC for 2-DG in human skeletal muscle is constant over a wide range of insulin concentrations and averages 1. 2.

show abstract

Myocardial Metabolism in Health and Disease

Gropler

Peterson

Dilsizian

2010

Cardiac CT, PET and MR

View full text Add to dashboard Cite

Myocardial glucose uptake evaluated by positron emission tomography and fluorodeoxyglucose during hyperglycemic clamp in IDDM patients. Role of free fatty acid and insulin levels

Cited by 5 publications

References 0 publications

The changes of cardiac energy metabolism with sodium-glucose transporter 2 inhibitor therapy

The changes of cardiac energy metabolism with sodium-glucose transporter 2 inhibitor therapy

Direct measurement of the lumped constant for 2-deoxy-[1-¹⁴C]glucose in vivo in human skeletal muscle

Myocardial Metabolism in Health and Disease

Contact Info

Product

Resources

About

Myocardial glucose uptake evaluated by positron emission tomography and fluorodeoxyglucose during hyperglycemic clamp in IDDM patients. Role of free fatty acid and insulin levels

Cited by 5 publications

References 0 publications

The changes of cardiac energy metabolism with sodium-glucose transporter 2 inhibitor therapy

The changes of cardiac energy metabolism with sodium-glucose transporter 2 inhibitor therapy

Direct measurement of the lumped constant for 2-deoxy-[1-14C]glucose in vivo in human skeletal muscle

Myocardial Metabolism in Health and Disease

Contact Info

Product

Resources

About

Direct measurement of the lumped constant for 2-deoxy-[1-¹⁴C]glucose in vivo in human skeletal muscle